drugset / Trial / NCT00314210

Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.

NCT00314210

Phase 3 Completed 575 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Timeline

Start
2006-03
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 50 mg
Subject Quetiapine Small molecule 150 mg
Subject Quetiapine Small molecule 300 mg

Indications